Despite the widespread adoption of integrated evidence planning, many organizations still treat Day 1 of launch as the clinical finish line in practice. Teams invest years building a comprehensive Phase III registration package and aligning internal functions around a fixed data set. The prevailing assumption is simple: secure regulatory approval with solid endpoints, and the therapy will be incorporated into clinical practice.
Today, approval alone rarely determines how a therapy is used over time.
In therapy areas where clinicians already have several established treatment options, the registration package starts to leave important questions unanswered almost as soon as the therapy is approved. Immunology is a clear example: multiple mechanisms of action, new indications and formulations, and the arrival of biosimilars mean that what clinicians need to know keeps shifting.
Responding to this requires treating Day 1 not as the culmination of clinical development, but as one point in an ongoing, responsive approach to evidence generation that begins well before launch.
Why therapy area context matters
Prescient’s regression analysis, evaluating more than 250 launches over five years across more than 30 countries, found that therapy area dynamics and the characteristics of each launch explain over 40% of the variation in launch outcomes. If context explains so much of the variation, a generic, template-driven evidence plan is unlikely to serve any launch well; evidence needs to be planned around the clinical realities of each disease area.
The key factors at play differ markedly between therapy areas. In rare disease settings, small populations and limited natural history data mean that registries, external control arms, and post-approval commitments often carry much of the evidentiary load. Where many effective treatments exist, the challenge is different: continued evidence generation is needed to show where a new therapy fits among established options.
Clinical questions extend beyond registration trials
Pivotal trials are designed to meet regulatory requirements in tightly controlled, selected patient populations. Clinical practice is far more varied.
Efficacy and safety remain foundational. However, in disease areas with extensive clinical experience across existing therapies, physicians often encounter questions that Phase III trials were not intended to answer:
Sequencing after inadequate response: “Where does this sit for a patient with an inadequate response to an anti-TNF or JAK inhibitor?”
Real-world durability: “What do treatment persistence and drug survival look like in routine practice, outside the confines of trial protocols?”
Complex comorbidities: “How does this therapy perform in patients presenting with metabolic, cardiovascular, or multi-organ involvement?”
Treatment change decisions: “For a patient who is stable on their regimen, what evidence is available on the potential benefits and risks of changing therapy?”
Clinicians reasonably rely on therapies with long track records, which means that positioning a less familiar option, whether earlier in the pathway or after prior advanced therapy, depends on credible comparative evidence. Head-to-head trials are rarely available at launch, so indirect treatment comparisons and network meta-analyses often have to fill the gap, and their limitations need to be anticipated. Payers and health technology assessment bodies are grappling with many of the same uncertainties, particularly around relative value, real-world outcomes, and budget impact. Without evidence on these specific questions, it is difficult for clinicians and decision-makers to judge where a recently approved therapy fits in care.
The role of Medical Affairs
Medical Affairs is well placed to inform evidence planning because, through advisory boards, insight gathering, and non-promotional scientific exchange on the disease area, it can identify unanswered questions and the evidence stakeholders are likely to need once a therapy is available.
This perspective is especially valuable in mature therapy areas. Working closely with RWE/HEOR, Market Access, and Clinical Development, Medical Affairs can help lead integrated evidence planning, a cross-functional process for ensuring evidence-generation activities reflect the needs of clinicians, payers, and guideline bodies.
Rather than waiting until 12 months prior to launch, organizations can begin planning as early as Phase II development, identifying where additional studies or analyses may be needed to support future decisions. Three priorities stand out:
- Build real-world evidence capabilities early: Prospective registries, observational studies, and fit-for-purpose secondary data such as claims and electronic health records can complement registration data by providing insight into treatment persistence, long-term outcomes, safety, and how therapies are used in practice. Once established, these programs create a foundation for answering questions that clinical trials alone cannot easily resolve. Data source feasibility, comparator capture, and acceptability to HTA bodies should be assessed before launch, as these gaps are difficult to fix retrospectively.
- Maintain a rolling evidence plan: A robust evidence strategy should include an ongoing program of analyses and studies on patient selection, comparative effectiveness, durability, and sequencing, with each activity tied to a specific scientific or access purpose, and post-authorization commitments such as PASS and PAES integrated into the plan rather than run in parallel.
- Keep pace with standards of care: As the number of treatment options in a disease area grows, expectations regarding clinical benefit often become more ambitious. Endpoints such as complete mucosal healing in inflammatory bowel disease or complete skin clearance in psoriasis may carry greater weight in treatment evaluation and guideline development. Medical Affairs should track these trends so that evidence-generation plans focus on the outcomes that matter most to clinicians and patients.
Reassessing the evidence strategy
A static launch plan captures decisions made at a particular point in time. A dynamic plan checks both that studies are progressing as expected and that the clinical and scientific assumptions behind them remain valid as the external landscape changes.
For this reason, teams should regularly review whether planned and ongoing studies still match stakeholder priorities. Monitoring the latest data across the therapy area, guideline updates, payer decisions, biosimilar availability, and field medical insights can help identify where adjustments may be needed.
For example, emerging clinical findings may point to patient subgroups that warrant further, appropriately designed investigation, while changes in access requirements could increase the importance of real-world outcomes data.
Deciding which evidence gaps are worth closing
Not every unanswered question justifies new evidence generation. Before committing resources, teams should test each gap against four questions. First, would the answer change a decision, such as a prescribing choice, a guideline recommendation, or a payer or HTA assessment? Questions that are scientifically interesting but would not alter practice belong lower on the list. Second, is this a genuine evidence gap or a communication gap? Field insights often reveal that clinicians are asking questions that existing trial data, post hoc analyses, or published literature can already answer; better synthesis and scientific exchange may be the right response, not a new study. Third, how consistently is the question being raised? A question heard across multiple markets, specialties, and stakeholder groups carries more weight than one raised by a single expert. Fourth, can credible evidence arrive in time? If a study will read out after the next guideline revision or HTA reassessment, its value diminishes considerably, and a faster approach, such as analysis of existing real-world data, may be more appropriate.
When we facilitate cross-functional integrated evidence planning and gap prioritization exercises, we use these questions to make the trade-offs explicit, including the risk of leaving a gap open. Framing gaps this way helps teams scenario-plan against where the standard of care is heading, not just where it is today, so the evidence plan stays forward-looking.
The same discipline applies to knowing when to stop. Once a question has been answered to the standard clinicians and decision-makers need, or when independent registries, academic consortia, or investigator-sponsored studies are already generating credible data on the same question, resources are usually better directed elsewhere.
Looking beyond launch
Historically, launch planning has centered on generating the evidence required for approval and early decision-making. In therapy areas with many treatment options, teams must also understand how new data, developments in standards of care, and stakeholder information needs may affect clinical practice, and adapt their evidence plans accordingly.
The objective should not be to generate the greatest possible volume of data, but to ensure that planned studies and analyses continue to address meaningful scientific and clinical questions.